Invision Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.50 M
- Company Age 6 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 75.81%
- Profit Growth -980.93%
- Ebitda -327.46%
- Net Worth -394.65%
- Total Assets 79.45%
About Invision Pharma
Invision Pharma Limited (IPL) is a Public Limited Indian Non-Government Company incorporated in India on 21 May 2018 (Six years and nine months 3 days old ). Its registered office is in Bangaluru, Karnataka, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Mukeshkumar, Nataraj Nanjundappa, and Chirag Mukeshkumar serve as directors at the Company.
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24304KA2018PLC113264
- Company No.
113264
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
21 May 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Invision Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mukeshkumar  | Director | 21-May-2018 | Current |
| Nataraj Nanjundappa | Director | 21-May-2018 | Current |
| Chirag Mukeshkumar | Director | 21-May-2018 | Current |
Financial Performance of Invision Pharma.
Invision Pharma Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 75.81% increase. The company also saw a substantial fall in profitability, with a 980.93% decrease in profit. The company's net worth observed a substantial decline by a decrease of 394.65%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Invision Pharma?
In 2023, Invision Pharma had a promoter holding of 99.92% and a public holding of 0.08%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Minova Life Sciences Private LimitedMukeshkumar and Chirag Mukeshkumar are mutual person
Invision Medi Sciences Private LimitedMukeshkumar, Nataraj Nanjundappa and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Invision Pharma?
Unlock and access historical data on people associated with Invision Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Invision Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Invision Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
